Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4018)	11/30/2001 12:02:15 AM
From: Mad2	Read Replies (2) \| Respond to of 5582

Actually Dan, I don't critize the deal with Wrigley. They are the major player in the gum business and the leverage they cam apply could certianly result in extracting greater value out of GUMM's IP or marketing agreements than anyone else. The fact that GUMM recieved a significant premium over book was benifical to GUMM. Any "complaint" I would have would be along the lines that GUMM shareholders have yet to realize any benifit. Record shows that GUMM insiders along with the Bio-Tech crew have done quite well.......yet GUMM stock is where it was at 3-4 years ago. I've heard all the reasons going back two years ago why GUMm was a great investiment.......all the while insiders were selling. Now the BioTech guys have bailed......IMO that doesn't bode well for GUMM. Anyway looks like GUMM is yet overvalued and simply a dead stock. Good luck to you as I have no position in GUMM mad2